740 related articles for article (PubMed ID: 33186492)
1. Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Yusuf S; Joseph P; Dans A; Gao P; Teo K; Xavier D; López-Jaramillo P; Yusoff K; Santoso A; Gamra H; Talukder S; Christou C; Girish P; Yeates K; Xavier F; Dagenais G; Rocha C; McCready T; Tyrwhitt J; Bosch J; Pais P;
N Engl J Med; 2021 Jan; 384(3):216-228. PubMed ID: 33186492
[TBL] [Abstract][Full Text] [Related]
2. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
[TBL] [Abstract][Full Text] [Related]
3. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
; Yusuf S; Pais P; Afzal R; Xavier D; Teo K; Eikelboom J; Sigamani A; Mohan V; Gupta R; Thomas N
Lancet; 2009 Apr; 373(9672):1341-51. PubMed ID: 19339045
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Roshandel G; Khoshnia M; Poustchi H; Hemming K; Kamangar F; Gharavi A; Ostovaneh MR; Nateghi A; Majed M; Navabakhsh B; Merat S; Pourshams A; Nalini M; Malekzadeh F; Sadeghi M; Mohammadifard N; Sarrafzadegan N; Naemi-Tabiei M; Fazel A; Brennan P; Etemadi A; Boffetta P; Thomas N; Marshall T; Cheng KK; Malekzadeh R
Lancet; 2019 Aug; 394(10199):672-683. PubMed ID: 31448738
[TBL] [Abstract][Full Text] [Related]
5. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Yusuf S; Lonn E; Pais P; Bosch J; López-Jaramillo P; Zhu J; Xavier D; Avezum A; Leiter LA; Piegas LS; Parkhomenko A; Keltai M; Keltai K; Sliwa K; Chazova I; Peters RJ; Held C; Yusoff K; Lewis BS; Jansky P; Khunti K; Toff WD; Reid CM; Varigos J; Accini JL; McKelvie R; Pogue J; Jung H; Liu L; Diaz R; Dans A; Dagenais G;
N Engl J Med; 2016 May; 374(21):2032-43. PubMed ID: 27039945
[TBL] [Abstract][Full Text] [Related]
6. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Thom S; Poulter N; Field J; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Bompoint S; Billot L; Rodgers A;
JAMA; 2013 Sep; 310(9):918-29. PubMed ID: 24002278
[TBL] [Abstract][Full Text] [Related]
7. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
Yusuf S; Pais P; Sigamani A; Xavier D; Afzal R; Gao P; Teo KK
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):463-71. PubMed ID: 22787067
[TBL] [Abstract][Full Text] [Related]
8. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
[TBL] [Abstract][Full Text] [Related]
9. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
Lonn EM; Bosch J; López-Jaramillo P; Zhu J; Liu L; Pais P; Diaz R; Xavier D; Sliwa K; Dans A; Avezum A; Piegas LS; Keltai K; Keltai M; Chazova I; Peters RJ; Held C; Yusoff K; Lewis BS; Jansky P; Parkhomenko A; Khunti K; Toff WD; Reid CM; Varigos J; Leiter LA; Molina DI; McKelvie R; Pogue J; Wilkinson J; Jung H; Dagenais G; Yusuf S;
N Engl J Med; 2016 May; 374(21):2009-20. PubMed ID: 27041480
[TBL] [Abstract][Full Text] [Related]
10. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
[TBL] [Abstract][Full Text] [Related]
11. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
[TBL] [Abstract][Full Text] [Related]
12. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Carey KM; Comee MR; Donovan JL; Kanaan AO
Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
[TBL] [Abstract][Full Text] [Related]
13. The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct.
Joseph P; Pais P; Dans AL; Bosch J; Xavier D; Lopez-Jaramillo P; Yusoff K; Santoso A; Talukder S; Gamra H; Yeates K; Lopez PC; Tyrwhitt J; Gao P; Teo K; Yusuf S;
Am Heart J; 2018 Dec; 206():72-79. PubMed ID: 30342297
[TBL] [Abstract][Full Text] [Related]
14. Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Muñoz D; Uzoije P; Reynolds C; Miller R; Walkley D; Pappalardo S; Tousey P; Munro H; Gonzales H; Song W; White C; Blot WJ; Wang TJ
N Engl J Med; 2019 Sep; 381(12):1114-1123. PubMed ID: 31532959
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban in Peripheral Artery Disease after Revascularization.
Bonaca MP; Bauersachs RM; Anand SS; Debus ES; Nehler MR; Patel MR; Fanelli F; Capell WH; Diao L; Jaeger N; Hess CN; Pap AF; Kittelson JM; Gudz I; Mátyás L; Krievins DK; Diaz R; Brodmann M; Muehlhofer E; Haskell LP; Berkowitz SD; Hiatt WR
N Engl J Med; 2020 May; 382(21):1994-2004. PubMed ID: 32222135
[TBL] [Abstract][Full Text] [Related]
16. Effects of a Polypill, Aspirin, and the Combination of Both on Cognitive and Functional Outcomes: A Randomized Clinical Trial.
Bosch JJ; O'Donnell MJ; Gao P; Joseph P; Pais P; Xavier D; Dans A; Lopez Jaramillo P; Yusuf S
JAMA Neurol; 2023 Mar; 80(3):251-259. PubMed ID: 36716007
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial.
Lafeber M; Grobbee DE; Schrover IM; Thom S; Webster R; Rodgers A; Visseren FL; Bots ML; Spiering W
Int J Cardiol; 2015 Feb; 181():193-9. PubMed ID: 25528311
[TBL] [Abstract][Full Text] [Related]
18. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
Soliman EZ; Mendis S; Dissanayake WP; Somasundaram NP; Gunaratne PS; Jayasingne IK; Furberg CD
Trials; 2011 Jan; 12():3. PubMed ID: 21205325
[TBL] [Abstract][Full Text] [Related]
19. Improving cardiovascular protection: focus on a cardiovascular polypill.
Barrios V; Escobar C
Future Cardiol; 2016 Mar; 12(2):181-96. PubMed ID: 26652213
[TBL] [Abstract][Full Text] [Related]
20. Polypill Strategy in Secondary Cardiovascular Prevention.
Castellano JM; Pocock SJ; Bhatt DL; Quesada AJ; Owen R; Fernandez-Ortiz A; Sanchez PL; Marin Ortuño F; Vazquez Rodriguez JM; Domingo-Fernández A; Lozano I; Roncaglioni MC; Baviera M; Foresta A; Ojeda-Fernandez L; Colivicchi F; Di Fusco SA; Doehner W; Meyer A; Schiele F; Ecarnot F; Linhart A; Lubanda JC; Barczi G; Merkely B; Ponikowski P; Kasprzak M; Fernandez Alvira JM; Andres V; Bueno H; Collier T; Van de Werf F; Perel P; Rodriguez-Manero M; Alonso Garcia A; Proietti M; Schoos MM; Simon T; Fernandez Ferro J; Lopez N; Beghi E; Bejot Y; Vivas D; Cordero A; Ibañez B; Fuster V;
N Engl J Med; 2022 Sep; 387(11):967-977. PubMed ID: 36018037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]